pharmaphorum August 30, 2024
Phil Taylor

Emergent BioSolutions has been given FDA approval to extend the indications for its smallpox vaccine ACAM2000 to include the prevention of mpox, currently deemed a public health emergency by the WHO.

ACAM200 can be used for people at high risk of mpox, according to the company, with the news causing shares in Emergent to spike more than 27% in pre-market trading. The virus that causes mpox (previously known as monkeypox) is in the same Orthopox group as the one that causes smallpox.

The approval comes as there were 1,000 new cases of mpox reported this week in the Democratic Republic of the Congo (DRC) alone, which is at the heart of the current outbreak, with cases also seen in a...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Related Articles:
Podcast: Jihye Han Compares First-In-Class Drug Regulation in the US and Europe
Reflecting on a milestone year for cell and gene therapies
Pharma Pulse 3/3/25: Will Tariffs Affect Branded Drug Prices? Pharmacists' Role in Medical Cannabis Counseling and Patient Education & more
Biotech startup pulls in $187M to make ‘multi-payload’ ADCs
Pharma’s Role in Ensuring Patient Access to Trustworthy Health Insights

Share This Article